(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...
Mar 29, 2012
0
0
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Sep 4, 2012
0
0
Hot flashes put a damper on women's health and productivity at work and pump up the cost of health care. A study published online this month in Menopause, the journal of the North American Menopause Society (NAMS), has put ...
Feb 22, 2013
0
0
Drugmaker Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor due to increasing ...
Jul 31, 2012
0
0
A new study that tracked what Alzheimer's disease and related disorders (ADRD) costs Medicare during three distinct stages of patient care suggests that the government insurer could realize substantial savings through efforts ...
Apr 10, 2012
0
0
(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.
Nov 7, 2012
0
0
Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...
Jul 30, 2013
0
0
Several more countries have approved Pfizer Inc.'s new rheumatoid arthritis medicine, a twice-a-day pill seen as likely to be a big moneymaker for the company.
Jul 15, 2013
0
0
(HealthDay) -- A U.S. Food and Drug Administration advisory panel on Monday will weigh the wisdom of allowing new clinical trials of a class of powerful painkillers for osteoarthritis. The drugs may have worked so well for ...
Mar 12, 2012
0
0
An experimental drug that failed to stop mental decline in Alzheimer's patients in the U.S. and Canada also showed some potential benefit in slowing brain plaque, fuller results of two major studies show.
Sep 11, 2012
0
0
